Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clostridium difficile (C. diff)
Biotech
Chasing Seres, Vedanta bags $107M to run phase 3 C. diff trial
While a funding freeze recently forced Finch to fold a rival program, Vedanta has reeled in $106.5 million to challenge Seres’ near-approval SER-109.
Nick Paul Taylor
Apr 25, 2023 9:40am
Ferring's research site closure signals shift from internal R&D
Apr 11, 2023 11:22am
Destiny seals C. diff therapy's phase 3 fate with Sebela
Feb 24, 2023 10:10am
FDA committee votes for Ferring's C. difficile therapy
Sep 23, 2022 10:15am
Summit will take scenic route up FDA mountain
Jul 14, 2022 11:29am
Equipped with new safety data, Seres eyes FDA approval
Jun 7, 2022 7:00am